Qubigen
Qubigen is an Australian AI drug design company offering an end-to-end Federated AI managed service that enables pharmaceutical companies, biotechs, and research institutions to collaboratively design novel drug candidates without exposing proprietary data, combining federated learning with molecular mechanics and quantum chemistry.
- Company typePrivate
- Founded2024
- HeadquartersMelbourne, Australia
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Qubigen does
Qubigen is an Australian AI-driven drug design company that operates a fully managed Federated AI service for pharmaceutical companies, biotech firms, and research institutions. Its flagship platform, FedAIDD (Federated AI Drug Design), enables secure AI training across distributed datasets without moving or exposing sensitive underlying data, directly addressing intellectual property protection concerns that have historically blocked collaborative AI training in pharma. The company was formed in 2024 through the merger of Presagen and Qubist, combining Presagen's Federated AI capabilities with Qubist's AI drug design and virtual screening expertise.
The platform architecture combines a proprietary machine learning library and tailored AI engines with molecular mechanics simulations, GPU-accelerated quantum chemistry, and bespoke virtual screening algorithms. Qubigen executes all molecular generation, optimization, and analysis as a managed service rather than offering self-service tooling, delivering end-to-end workflows from project selection through hit-to-lead, SAR/SPR evaluation, lead optimization, and ADMET assessment. Reported performance claims include 14x faster and 187x more cost-effective operation than conventional approaches, supported by case-study evidence such as a novel compound designed in 3 days and sub-micromolar binding predictions validated experimentally.
Qubigen's go-to-market is enterprise sales-led, engaging large pharmaceutical companies and research institutions directly through CEO-led outreach, data collaboration partnerships, and major industry events like BIO International Convention 2026. Revenue mechanics are primarily project-based managed services, complemented by a Data Collaboration Partner model in which contributing institutions share in upside from resulting drug candidates. The company maintains headquarters at the Bio21 Institute in Parkville, Victoria, and a regional office at Adelaide's Tech Central, with active partnerships spanning Australia, the US (Dana-Farber), Europe (DZIF), and Japan (IMC). Strategic backing comes from SYNthesis BioVentures, whose partners occupy three board seats.
Qubigen firmographics
Firmographics- Name
- Qubigen
- Legal name
- Qubigen
- Website
- https://qubigen.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Qubigen is an Australian AI drug design company offering an end-to-end Federated AI managed service that enables pharmaceutical companies, biotechs, and research institutions to collaboratively design novel drug candidates without exposing proprietary data, combining federated learning with molecular mechanics and quantum chemistry.
- Ownership category
- akta.pro rank
Qubigen industry classification
Industry- Product category
- AI Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design Services (541512)
- SIC
- Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand) (HDAGAEAB)
Keywords
Where Qubigen is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
Qubigen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Managed Drug Design Service: Qubigen provides end-to-end AI drug design as a fully managed service. All molecular generation, optimization, and analysis is performed by Qubigen's AI workflows as a service to clients and partners. Revenue likely comes from project-based fees, service contracts, and potentially milestone payments tied to drug discovery outcomes.
- Data Collaboration Partnership Model: Qubigen offers Data Collaboration Partners the opportunity to participate in cooperative projects to design novel medicines. Partners contribute data to a larger mission and enjoy potential upside from resulting drug candidates, potentially including commercialization rights or milestone payments.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Qubigen product offering
Product offeringCore offering
Qubigen provides end-to-end AI drug design as a managed service using its proprietary FedAIDD (Federated AI Drug Design) platform. The company combines secure federated learning with molecular mechanics simulations and quantum chemistry to design, optimize, and deliver novel small-molecule drug candidates for pharmaceutical companies and research institutions, without ever moving or directly accessing client proprietary data.
Product overview
Qubigen is an end-to-end AI drug design company that offers a unified platform combining its FedAIDD (Federated AI Drug Design) system with proprietary application-specific AI workflows. The platform operates as a fully managed drug design service where Qubigen scientists perform all molecular generation, optimization, and analysis using federated AI, molecular mechanics, and quantum chemistry capabilities. The company provides end-to-end services from project selection through molecule generation to virtual screening and validation, targeting pharmaceutical companies and research institutions seeking to design novel medicines without exposing sensitive intellectual property.
Differentiator
Problem solved
Functional benefit
Products and services
- FedAIDD (Federated AI Drug Design) Managed Service Qubigen's proprietary Federated AI system for Drug Design enables secure AI training across distributed datasets without moving or exposing sensitive underlying data. Delivered as an end-to-end managed service where Qubigen scientists perform molecular generation, optimization, and analysis for pharmaceutical companies and research institutions.
- Virtual Screening & Quantum Chemistry Services Service offering that uses proprietary virtual screening algorithms combining molecular mechanics simulations for specific target proteins with GPU-accelerated quantum chemistry for precise evaluation of binding properties, enabling assessment and screening of novel compounds against protein targets.
Quantifiable outcome
- 14x faster and 187x more cost-effective than conventional approaches
- +5 more outcomes
Companies that use Qubigen
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Qubigen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Qubigen partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered major, core and minor.
- German Center for Infection Research (DZIF)majorJoint project with Qubigen to develop antiviral drugs using federated AI technology. The project leverages Qubigen's FedAIDD platform to enable secure AI training across distributed datasets without disclosing sensitive underlying data, drawing on antiviral research from the Nucleoside Booster project. The initiative aims to generate novel small-molecule drug candidates with improved antiviral activity and shortened development timelines.
- Institute of Microbial Chemistry (IMC) JapanmajorCollaborative partner in the federated AI antiviral drug development project alongside DZIF. Contributes to the multi-institutional effort to generate novel small-molecule drug candidates using Qubigen's secure AI platform.
- QIMR BerghofercoreOngoing collaboration combining QIMR Berghofer's expertise in translational cancer biology with Qubigen's privacy-preserving Federated AI platform to identify novel small-molecule candidates targeting tumorigenesis and cancer progression. Multiple compounds have progressed from computational discovery to experimental validation, with overlapping activity in binding and functional assays demonstrating biological relevance.
- Dana-Farber Cancer InstitutecoreResearch collaboration with Dr. Srinivas Viswanathan's team focusing on discovery of novel small-molecule candidates for a rare and aggressive type of kidney cancer. Using Qubigen's privacy-preserving Federated AI platform and advanced computational modeling to identify and rank potential compounds that may disrupt key oncogenic mechanisms.
- SYNthesis BioVenturescoreStrategic partner and investor in Qubigen. Managing Directors Dr. Amir Zalcenstein and Dr. Fabio Turatti, and Founding Partner Prof. Andrew Wilks serve on Qubigen's board. SYNthesis brings drug development expertise and commercialization capabilities.
- Chordoma FoundationminorPatient advocacy foundation partner with logo displayed on Qubigen partnerships page, indicating collaboration on rare cancer drug discovery.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Qubigen competitors and assessment
Company assessmentDirect peers
- Owkin: Federated AI company applying privacy-preserving learning to biomedical and pharma R&D data across hospitals and life sciences partners. Most direct peer to Qubigen's federated-AI-for-drug-discovery positioning.
- Atomwise: AI drug design company using structure-based convolutional neural networks (AtomNet) for virtual screening and hit discovery. Direct competitor in AI-driven small-molecule virtual screening.
- XtalPi: AI- and physics-based drug discovery platform combining quantum mechanics, molecular dynamics, and machine learning to predict molecular properties. Closest direct peer to Qubigen given shared use of quantum chemistry and AI for small-molecule candidate generation.
- Insilico Medicine: AI-driven drug discovery company using generative AI and deep learning to identify novel targets and design small-molecule candidates end-to-end. Operates in the same AI-native small-molecule design category as Qubigen.
- Insitro: Machine-learning-driven drug discovery company combining high-throughput biology with predictive models to generate therapeutic candidates. Comparable business model of AI-native drug design services for pharma partners.
- BenevolentAI: AI drug discovery company combining knowledge graphs and ML to identify novel targets and drug candidates for pharma partners. Comparable AI-service-for-pharma positioning.
Broad incumbents
- Isomorphic Labs: Alphabet/DeepMind spinout applying AlphaFold-derived AI to drug design and partnership-based pharma programs. Established player with deeper resources in AI-native drug discovery.
- Recursion Pharmaceuticals: Public clinical-stage TechBio combining high-throughput wet-lab experimentation with AI to discover and develop medicines at scale. Larger, broader incumbent in AI-driven drug discovery.
- Schrödinger: Public computational chemistry and materials science platform providing physics-based simulation and ML software for drug discovery. A broader incumbent offering overlapping capabilities through software licensing rather than managed services.
Others
- MELLODDY: Pharma consortium that ran a federated, privacy-preserving machine learning platform across multiple pharmaceutical companies' chemical libraries. Directly comparable as a federated-learning-for-drug-discovery effort, though structured as a multi-pharma consortium rather than a company.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Qubigen social profiles
Digital presenceQubigen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Qubigen leadership team
Management profileNumber of profiles
Profiles13 records
Qubigen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Qubigen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Qubigen
What does Qubigen do?
Qubigen provides end-to-end AI drug design as a managed service using its proprietary FedAIDD (Federated AI Drug Design) platform. The company combines secure federated learning with molecular mechanics simulations and quantum chemistry to design, optimize, and deliver novel small-molecule drug candidates for pharmaceutical companies and research institutions, without ever moving or directly accessing client proprietary data.
Is Qubigen a public or private company?
Qubigen is a private company. It is classified as venture growth investor backed and is currently operating.
When was Qubigen founded?
Qubigen was founded in 2024. It employs 1 to 10 people.
Where is Qubigen based?
Qubigen is headquartered in Melbourne, Australia, in the Oceania region.
How does Qubigen make money?
Two revenue lines are on record. Managed Drug Design Service is the primary driver. The others are data Collaboration Partnership Model.
Who are Qubigen's main competitors?
Direct peers on record are Owkin, Atomwise, XtalPi, Insilico Medicine, Insitro and BenevolentAI. Broad incumbents are Isomorphic Labs, Recursion Pharmaceuticals and Schrödinger. MELLODDY is listed as an others.
Does Qubigen have an API?
No public API is recorded for Qubigen.
What industry is Qubigen in?
Qubigen's product category is AI Drug Discovery Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HDAGAEAB, Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand). Its NAICS code is 541714 and its SIC code is 7373.